Hamza Suria, AnaptysBio CEO

The biotech be­hind Glax­o­SmithK­line's PD-1 just scored a $250M cash deal for roy­al­ties

With Mer­ck and Bris­tol My­ers Squibb still dom­i­nat­ing the PD-(L)1 space and the threat of low­er-cost op­tions com­ing from be­hind, is there still room for Glax­o­SmithK­line’s check­point in­hibitor — the sev­enth to mar­ket — to make bil­lions? For Sagard Health­care Roy­al­ty Part­ners, the an­swer is yes.

Sagard has plumped down $250 mil­lion in cash to buy out the 8% roy­al­ty Anap­tys­Bio owns on Jem­per­li sales be­low $1 bil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.